ReviewDiabetology & metabolic syndrome2022
The effects of olive leaf extract on cardiovascular risk factors in the general adult population: a systematic review and meta-analysis of randomized controlled trials.
Review in Diabetology & metabolic syndrome, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07668791 (Efficacy Study of the Supplementation of a Food Supplement Consisting of the Combination of an Olive Extract), which is not on this map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy Study of the Supplementation of a Food Supplement Consisting of the Combination of an Olive Extract (Olea Europea L., Fruit), and Myrtle Extract (Myrtus Communis L. Leaves) for the Improvement of Lipid Metabolism in Subjects Eith Slightly Altered Cholesterolemia Values: Single-center, Controlled, Randomized, Parallel-arm, Double-blind Clinical Study
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Plant-Based Diets Reduce Blood Pressure: A Systematic Review of Recent Evidence.Current hypertension reports · 2023Pooled it
- Trial
- A comprehensive review ofRSC advances · 2026Review
- Effects of Olive Leaf Extract on Anxiety Symptoms and Metainflammation in Women with Excess Weight: A Randomized Double-Blind Placebo-Controlled Pilot Trial.Life (Basel, Switzerland) · 2026Article
- Retrospective Analysis of a Quince, Olive Leaf, and Amaranth Nutraceutical in Patients with Metabolic Syndrome.Medicina (Kaunas, Lithuania) · 2025Observational
- Olive Oil Industry By-Products as a Novel Source of Biophenols with a Promising Role in Alzheimer Disease Prevention.Molecules (Basel, Switzerland) · 2024Review
- From by-products to new application opportunities: the enhancement of the leaves deriving from the fruit plants for new potential healthy products.Frontiers in nutrition · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this systematic review and meta-analysis was to determine the effect of olive leaf extract (OLE) supplementation on cardiovascular-related variables, including lipid, glycemic, inflammatory, liver and renal-related factors, as well as blood pressure.
methodsPubMed, ISI Web of Science, Scopus, and Cochrane library were searched, up to October 2021, for relevant controlled trials. Mean differences and standard deviations were pooled for all outcomes, using a random-effects model. The methodological quality, as well as quality of evidence were assessed using standard tools.
resultsTwelve studies (n = 819 participants) were included in our analyses. Overall analyses showed that OLE supplementation significantly decreased triglyceride (TG) levels (WMD = - 9.51 mg/dl, 95% CI - 17.83, - 1.18; P = 0.025; I
conclusionThe present study revealed that supplementation with OLE yielded beneficial effects for blood pressure and lipid profile in adults, especially in patients with hypertension. As the quality of evidence for glucose hemostasis variables, liver, kidney, and inflammatory markers, were low-to-very low, higher quality RCTs may impact the overarching results. This study was registered at PROSPERO with the code CRD42022302395.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.